Bevacizumab: off-label use in ophthalmology (Q36977418)

17 August 2017

8 references

25 April 2019

19 June 2019

27 September 2019

27 November 2019

13 December 2019

14 October 2020

5 November 2020

26 January 2021

Bevacizumab: off-label use in ophthalmology (English)

1 reference

retinal neovascularization

17 August 2017

1 reference

27 September 2019

1 reference

27 November 2019

1 reference

13 December 2019

1 reference

3 references

14 October 2020

5 November 2020

26 January 2021

angiogenesis inhibitor

1 reference

5 November 2020

1 reference

26 January 2021

Salvatore Grisanti

1 reference

17 August 2017

Focke Ziemssen

series ordinal

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 November 2007

1 reference

Indian Journal of Ophthalmology

17 August 2017

9 references

17 August 2017

25 April 2019

19 June 2019

27 September 2019

27 November 2019

13 December 2019

14 October 2020

5 November 2020

26 January 2021

1 reference

17 August 2017

1 reference

17 August 2017

417-420

1 reference

Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported

17 August 2017

8 references

25 April 2019

19 June 2019

27 September 2019

27 November 2019

13 December 2019

14 October 2020

5 November 2020

Intraocular application of bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks

26 January 2021

copyrighted

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Effects of bevacizumab on retinal function in isolated vertebrate retina

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Penetration of bevacizumab through the retina after intravitreal injection in the monkey.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Case of anterior uveitis after intravitreal injection of bevacizumab

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Evaluation of in vitro effects of bevacizumab (Avastin) on retinal pigment epithelial, neurosensory retinal, and microvascular endothelial cells

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Regression of retinal and iris neovascularization after intravitreal bevacizumab (Avastin) treatment.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Testing intravitreal toxicity of bevacizumab (Avastin).

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study

4 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2635984

Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure.

4 September 2018

1 reference

12 December 2020

Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD

1 reference

12 December 2020

Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone

1 reference

12 December 2020

Intravitreal bevacizumab for idiopathic choroidal neovascularization after previous injection with posterior subtenon triamcinolone

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration: a short-term study

1 reference

12 December 2020

Acute endophthalmitis following intravitreal bevacizumab (Avastin) injection

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia

1 reference

12 December 2020

Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells

1 reference

12 December 2020

Safety of intravitreal injection of bevacizumab in rabbit eyes

1 reference

12 December 2020

Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab

1 reference

12 December 2020

Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration

1 reference

12 December 2020

Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration

1 reference

12 December 2020

Choroidal neovascularization treated with intravitreal injection of bevacizumab (Avastin) in angioid streaks

1 reference

12 December 2020

Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration

1 reference

12 December 2020

Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia

1 reference

12 December 2020

Identifiers

DOI

10.4103/0301-4738.36474

1 reference

17 August 2017

1 reference

17 August 2017

PubMed publication ID

17951896

1 reference